|
Volumn 298, Issue 1, 2010, Pages
|
Chymase: The other ACE?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALISKIREN;
ANGIOTENSIN CONVERTING ENZYME 2;
ANGIOTENSIN I;
ANGIOTENSIN II;
ANGIOTENSIN RECEPTOR ANTAGONIST;
CATHEPSIN G;
CHYMASE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIPEPTIDYL CARBOXYPEPTIDASE;
LEPTIN RECEPTOR;
BLOOD PRESSURE;
DIABETIC NEPHROPATHY;
DISEASE COURSE;
DRUG EFFECT;
DRUG EFFICACY;
EDITORIAL;
ENZYME ACTIVITY;
ENZYME BLOOD LEVEL;
ENZYME INHIBITION;
HEMODYNAMICS;
HUMAN;
HYPERTENSION;
NONHUMAN;
PLASMA RENIN ACTIVITY;
PRIORITY JOURNAL;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
RISK FACTOR;
VASOCONSTRICTION;
ANIMAL;
DIABETES MELLITUS;
DISEASE MODEL;
GENETICS;
KIDNEY;
METABOLISM;
MOUSE;
NOTE;
PHYSIOLOGY;
SIGNAL TRANSDUCTION;
ANGIOTENSIN II;
ANIMALS;
CHYMASES;
DIABETES COMPLICATIONS;
DIABETIC NEPHROPATHIES;
DISEASE MODELS, ANIMAL;
HUMANS;
HYPERTENSION;
KIDNEY;
MICE;
PEPTIDYL-DIPEPTIDASE A;
RECEPTORS, LEPTIN;
SIGNAL TRANSDUCTION;
|
EID: 74049088290
PISSN: 1931857X
EISSN: 15221466
Source Type: Journal
DOI: 10.1152/ajprenal.00641.2009 Document Type: Editorial |
Times cited : (31)
|
References (6)
|